MEM INST OSWALDO CRUZ, RIO DE JANEIRO, FAST TRACK
PAGES: DOI: 10.1590/0074-02760170268 Letter to the editor
Insights on potential prophylactic activity of a sofosbuvir-based therapy against Zika

Estevão Portela Nunes1, Giselle Barbosa-Lima1,2,4, Yasmine Rangel Vieira1,2,4, José Cerbino-Neto1, Fernando A. Bozza1,2, Patrícia T. Bozza2, Valdilea G. Veloso1, Karin Brüning 3, Thiago Moreno L. Souza1,2,4,+

1Instituto Nacional de Infectologia Evandro Chagas (INI), Fiocruz, Rio de Janeiro, RJ, Brazil.
2Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
3BMK Consortium: Blanver Farmoquímica Ltda; Microbiológica Química e Farmacêutica Ltda; Karin Bruning & Cia. Ltda, São Paulo, Brazil.
4National Institute for Science and Technology on Innovation on 30 Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil.

Abstract

Sofosbuvir, clinically approved anti-hepatitis C virus (HCV) drug, inhibits Zika virus (ZIKV) replication. We wonder whether HCV-positive patients under sofosbuvir-based therapy would be less likely to have Zika. Indeed, whereas 8 of 68 untreated individuals had Zika, no case was registered among 21 individuals under this therapy.

+ Correspondence Author:
Thiago Moreno L. Souza, PhD
Fundação Oswaldo Cruz Centro de Desenvolvimento Tecnológico em Saúde (CDTS)
Instituto Oswaldo Cruz (IOC) Pavilhão Osório de Almeida, sala 16
Av. Brasil 4365, Manguinhos, Rio de Janeiro - RJ, Brasil, CEP 21060340
Tel: +55 21 2562-1311
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

CONTACT US

Memórias do Instituto Oswaldo Cruz

Av. Brasil 4365, Castelo Mourisco
sala 201, Manguinhos, 21040-900
Rio de Janeiro, RJ, Brazil

Tel.: +55-21-2562-1222

This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

twitterfacebook

SUPPORT PROGRAM

marca fiocruzmarca brasil
marca faperjmarca cnpqmarca capes n marca cope